Abstract
Tuberculosis caused by Mycobacterium tuberculosis is an infectious bacterial disease which is a leading cause of mortality affecting more than 9 million people worldwide. The current standard regimens that are available for the treatment of TB are severely hampered due to the occurrence of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains of Mycobacterium tuberculosis. In the past few years, a huge and constantly expanding effort has been developed to understand the chemical-biological interaction of many new anti-tubercular drugs and their targets in mathematical terms. Here, we have elected to review only those studies concerning 2D and 3D QSAR models that contain different DFT based descriptors as their parameters.
Keywords: Tuberculosis, 2D QSAR, 3D QSAR, DFT.
Current Pharmaceutical Design
Title:DFT Based QSAR/QSPR Models in the Development of Novel Anti-tuberculosis Drugs Targeting Mycobacterium tuberculosis
Volume: 20 Issue: 27
Author(s): Sanchaita Rajkhowa and Ramesh C. Deka
Affiliation:
- Department of Chemical Sciences, Tezpur University, Napaam, Tezpur, Assam-784028, India.,India
Keywords: Tuberculosis, 2D QSAR, 3D QSAR, DFT.
Abstract: Tuberculosis caused by Mycobacterium tuberculosis is an infectious bacterial disease which is a leading cause of mortality affecting more than 9 million people worldwide. The current standard regimens that are available for the treatment of TB are severely hampered due to the occurrence of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains of Mycobacterium tuberculosis. In the past few years, a huge and constantly expanding effort has been developed to understand the chemical-biological interaction of many new anti-tubercular drugs and their targets in mathematical terms. Here, we have elected to review only those studies concerning 2D and 3D QSAR models that contain different DFT based descriptors as their parameters.
Export Options
About this article
Cite this article as:
Rajkhowa Sanchaita and Deka C. Ramesh, DFT Based QSAR/QSPR Models in the Development of Novel Anti-tuberculosis Drugs Targeting Mycobacterium tuberculosis, Current Pharmaceutical Design 2014; 20(27) . https://dx.doi.org/10.2174/1381612819666131118165824
| DOI https://dx.doi.org/10.2174/1381612819666131118165824 |
Print ISSN 1381-6128 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Allegations from Whistleblowers
- Publishing Ethics
- Increase Visibility Of Your Article
- Self Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
Current Drug Targets Timely Identification of Disease by Parallel Real-time Automated Processing of Huge Medical Databases of Images Distributed Geographically, through Knowledge Sharing
Current Bioinformatics Green Synthesis of Novel Phthalimide Derivatives of Aspirin and P-aminosalicylic Acid as Potential Analgesic- antipyretic and Anti-tuberculosis Agents
Letters in Organic Chemistry Perspectives on the Development of Novel Potentially Active Quinolones Against Tuberculosis and Cancer
Mini-Reviews in Medicinal Chemistry Preclinical Study of New TB Drugs and Drug Combinations in Mouse Models
Recent Patents on Anti-Infective Drug Discovery Recent Advances in the Synthesis of New Antimycobacterial Agents Based on the 1H-1,2,3-Triazoles
Current Topics in Medicinal Chemistry Selection of Microbial T-Cell Epitopes for Immune-Diagnosis, Immune- Therapy and Vaccine Design
Current Pharmacogenomics IL-10 Promoter -592 Polymorphism may Influence Susceptibility to HIV Infection in South Indian Population
Current HIV Research Editorial: Comparison of Forgotten Surgical Techniques for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Nanostructured Therapeutic Carriers for Tuberculosis Treatment: Approaches & Challenges
Recent Patents on Anti-Infective Drug Discovery Treatment of Central Nervous System Tuberculosis Infections and Neurological Complications of Tuberculosis Treatment
Current Pharmaceutical Design Drug Resistance of Antitubercular Agents at the Genetic Level in Mycobacterium Species: A Road Map to Drug Development for Counteracting the Resistance
Mini-Reviews in Organic Chemistry Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent
Current Drug Discovery Technologies Multiple-Dose Pharmacokinetics of Efavirenz with and without the Use of Rifampicin in HIV-Positive Patients
Current HIV Research Protein Kinase Inhibitors as Potential Antimicrobial Drugs Against Tuberculosis, Malaria and HIV
Current Pharmaceutical Design Experimental and Clinical Studies on Rifacinna® - The New Effective Antituberculous Drug (Review)
Recent Patents on Anti-Infective Drug Discovery Selecting the Components for a Safe and Efficient Tuberculosis Subunit Vaccine - Recent Progress and Post-Genomic Insights
Current Pharmaceutical Biotechnology “Nano-Biomaterials” – A New Approach Concerning Multi-Drug Resistant Tuberculosis (MDR-TB)
Pharmaceutical Nanotechnology Nanoformulations of Moxifloxacin, Econozole and Ethionamide as Novel Treatment Regimens Against MDR TB - An Experimental Study
Current Nanoscience New Insights on the Nature of Latent Tuberculosis Infection and its Treatment
Inflammation & Allergy - Drug Targets (Discontinued)




